Fiche centre
Medical University of South Carolina
Charleston — United States
Essais liés38clinical trials
VilleCharlestonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00756769
Essais cliniques associés
38| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Mycophenolate Mofetil | Lupus | Phase 2 | NCT05538208 | The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study | RECRUITING |
| Acalabrutinib | Cancer | Phase 2 | NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | Cancer | Phase 2 | NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | RECRUITING |
| TAK-935 | Épilepsie | Phase 1/2 | NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| TAK-935 | Épilepsie | Phase 2 | NCT03650452 | ELEKTRA — A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Soticlestat | Épilepsie | Phase 3 | NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | COMPLETED |
| Biopsy Procedure | Cancer | Phase 2/3 | NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | RECRUITING |
| Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters | Épilepsie | Non applicable | NCT06143293 | RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS | ACTIVE_NOT_RECRUITING |
| Low Dose Mesenchymal Stem Cells (MSCs) | Lupus | Phase 2 | NCT02633163 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | COMPLETED |
| CABA-201 | Lupus | Phase 1/2 | NCT06121297 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | RECRUITING |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| GBPDC: Gut-Brain in PD Consortium Master Protocol | Parkinson | À vérifier | NCT07567794 | GBPDC: Gut-Brain in PD Consortium Master Protocol | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Bone Scan | Cancer | Phase 2/3 | NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | SUSPENDED |
| CNP-106 | Myasthénie | Phase 1/2 | NCT06106672 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | Myasthénie | À vérifier | NCT06002945 | EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | COMPLETED |
| SLEIGH — Systemic Lupus Erythematosus in Gullah Health | Lupus | À vérifier | NCT00756769 | SLEIGH — Systemic Lupus Erythematosus in Gullah Health | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| ALLO-329 | Lupus | Phase 1 | NCT07085104 | RESOLUTION — A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease | RECRUITING |
| Biospecimen Collection | Cancer | Phase 2/3 | NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | RECRUITING |
| Actual device PFO closure | Migraine | Non applicable | NCT04100135 | RELIEF — GORE® CARDIOFORM Septal Occluder Migraine Clinical Study | TERMINATED |
| Imaging Biomarkers of FOG Response to DBS | Parkinson | Phase 4 | NCT06951906 | Imaging Biomarkers of FOG Response to DBS | RECRUITING |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Paradise Ultrasound Renal Denervation Treatment | Hypertension | À vérifier | NCT06297291 | US GPS — Global Paradise System US Post Approval Study | RECRUITING |
| The Paradise® Renal Denervation Ultrasound System | Hypertension | Non applicable | NCT02649426 | RADIANCE-HTN — A Study of the ReCor Medical Paradise System in Clinical Hypertension | ACTIVE_NOT_RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Mexiletine | Sclérose latérale amyotrophique | Phase 2 | NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | COMPLETED |
| Low Dose Mesenchymal Stem Cells (MSCs) | Lupus | Phase 1 | NCT03171194 | Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus | COMPLETED |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |
| RNS® System | Épilepsie | Phase 4 | NCT00572195 | RNS® System LTT Study | COMPLETED |